Michael Schultz Email

Chief Science Officer . Viewpoint Molecular Targeting

Current Roles

Employees:
15
Revenue:
$3M
About
Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. The Company's leading 𝛼-particle radiotherapies are designed to deliver powerful alpha radiation specifically to cancer cells utilizing specialized targeting peptides. Viewpoint is also developing complementary diagnostics that utilize the same targeting peptide which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-𝛼-NET) programs are entering Phase 1 imaging studies, to be followed by Phase 1/2a therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at two leading academic institutions.
Viewpoint Molecular Targeting Address
2500 Crosspark Rd
Coralville, IA
United States
Viewpoint Molecular Targeting Email
Viewpoint Molecular Targeting Phone Numbers
865-356-1861

Past Companies

Viewpoint Molecular Targeting, Inc.Chief Science Officer
University of IowaAssociate Professor

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.